The Geography of Drug Approvals
How can regulators look at the same data and get different results?
The goal of regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the African Medicines...
Online Exclusives
Will the White House Continue to Fund the ACA’s Health Navigator...
The Trump administration must decide by September whether to continue funding “navigator” organizations that help individuals buy health-care plans through the Affordable Care Act...
Predicting Venous Thromboembolism in Patients With Non-Hodgkin Lymphoma
Author’s Perspective
Study author Roberto Mario Santi, MD: “Patients with non-Hodgkin lymphoma (NHL) have a high risk of venous thromboembolism (VTE) during the first six...
News
From the Blood Journals
Number of Older Patients Receiving AlloHCT Increased Over the Past Decade
Historically, older adults have not been considered optimal candidates for hematopoietic cell transplantation (HCT) because of concerns about transplant-related toxicity and mortality. Over the...
Examining Nilotinib to Prevent Post-Transplant Relapse in Patients With Ph+ Leukemia
In previous research published in Blood, Paul A. Carpenter, MBBS, from the Fred Hutchinson Cancer Research Center in Seattle, Washington, and co-authors determined that...
Latest Videos
Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML
Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an "impressive" response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr....
Jae Hong Park, MD: Improving Outcomes, Minimizing Toxicity With CAR T-Cell...
Dr. Park reviews two studies identifying characteristics that can improve durability of outcome, without increasing toxicity, in patients with B-cell acute lymphocytic leukemia.
Frederick Locke, MD: CAR T-Cell Therapy in Relapsed/Refractory NHL
Based on results of the ZUMA-1 trial, axicabtagene ciloleucel was submitted to the FDA earlier this year for patients with chemotherapy-refractory, aggressive non-Hodgkin lymphomas....
Mathias Rummel, MD, PhD: Bendamustine-Rituximab “StiL” Beats R-CHOP for Indolent Lymphomas
Ten-year results from the randomized, phase III StiL trial show that bendamustine plus rituximab leads to longer progression-free survival than R-CHOP in patients with...
On Location
Is Anticoagulant Therapy to Prevent Recurrent VTE Worth the Bleeding Risk in Older Patients With Cancer?
Though anticoagulants are common frontline treatment for patients with venous thromboembolism (VTE), patients with cancer...
Phase II Results Show Activity of Polatuzumab Vedotin Combination in DLBCL
The CD79b-targeting antibody drug conjugate polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone...
Evaluating HCT Outcomes in Patients With Beta-Thalassemia
Hematopoietic cell transplantation (HCT) is associated with a disease-free survival rate of 90 percent at...
Fourth Drug’s the Charm? Comparing Combination Therapies in the Myeloma XI Trial
Triplet combinations of anti-myeloma induction therapies lead to deeper, longer remissions than doublet combinations. Results...
Ropeginterferon Alfa-2B Versus Hydroxyurea in Patients With Polycythemia Vera
Treatment with ropeginterferon alfa-2B, a mono-pegylated proline interferon, reduced JAK2 allele burden in patients with...
Fostamatinib Improves Platelet Counts in Certain Patients With Heavily Pretreated ITP
In a phase II study published in Blood, the oral SYK inhibitor fostamatinib was safe...
Latest Headlines
ASH Directions
ASH Selects Outstanding Trainees for Award Programs, Honorific Award Winners, and more
ASH Selects Outstanding Trainees for Award Programs
2017 ASH Research Training Award for Fellows
ASH selected 11 fellows for the 2017 ASH Research Training Award for...
ASH Co-Hosts Congressional Briefing on Sickle Cell Disease, Blood Journal’s Impact On the Rise,...
ASH Co-Hosts Congressional Briefing on Sickle Cell DiseaseThe American Society of Hematology (ASH) co-hosted a congressional briefing on sickle cell disease (SCD) and gene...
Ned Sharpless Named New NCI Director, 2017 Pew-Stewart Cancer Research Scholars Announced, and more
Norman Sharpless Named Director of the National Cancer Institute
Norman “Ned” Sharpless, MD, has been appointed director of the National Cancer Institute (NCI) by President...
Remembering H. Jean Khoury, NCI Funds Standardization of Cancer Genomic Data, and more
Remembering H. Jean Khoury (1967-2017)
H. Jean Khoury, MD, an expert in hematologic malignancies at the Winship Cancer Institute of Emory University, died at age...
Remembering Neil Abramson, MD, AACC Announces Clinical Chemistry Trainee Council Educational Initiative, and more
Remembering Neil Abramson, MD (1937-2017)
Neil Abramson, MD, a hematologist/oncologist who served as a Blood Special Section Editor from 2008-2012, passed away at the age...
The Geography of Drug Approvals
How can regulators look at the same data and get different results?
The goal of regulatory bodies such as the U.S. Food and Drug Administration...
It Runs in the Blood
For these doctors, hematology is “the family business”
The term “family business” may conjure images of stores, restaurants, and other commercial enterprises, but it turns...
Show Me the Money? Show Us the Data!
How will NIH’s new requirement that federally funded clinical trials report outcomes affect researchers?
The merits and cautions of data sharing have long been a...
